Medicinal and Pharmaceutical Chemistry — Design, Synthesis and Testing of New Anti-Bacterial Agents
This project would appeal to those with interests in pharmaceutical applications of medicinal and protein chemistry.
Pseudomonas aeruginosa is the most common respiratory pathogen in patients with cystic fibrosis and causes systemic infections in patients who are immunosuppressed as a result of severe burns, cancer and AIDS. This project will build upon our initial results (from a project aimed at developing new agents for the detection of this bacterium [PW Groundwater et al., Org. & Biomol. Chem., 2008, 8, 682; doi: 10.1039/b716978g]) and will aim to selectively release specific antibiotics within Pseudomonas aeruginosa, thereby improving their uptake and efficacy. This project would appeal to those with interests in pharmaceutical applications of medicinal and protein chemistry.
Want to find out more?
The opportunity ID for this research opportunity is: 938
Other opportunities with Professor Paul Groundwater
Other opportunities with Dr W Bret Church
- Structure-based drug design with Kynurenine Aminotransferase-I
- Informatics and Bioinformatics-based Approaches to Protein-Ligand Interaction
- Structure-based drug design with Soluble Epoxide Hydrolase
- Understanding the Switch between Enzyme and Signaling Behaviours in Human Group IIA Secreted Phospholipase A2 by Inhibitory Intervention
Other opportunities with Professor David (Dai) Hibbs